Xencor, Inc. (XNCR) Stock Grade

About Xencor, Inc.'s fundamentals

Xencor is a biotechnology company with a market capitalization of $1.9 billion that has demonstrated revenue growth of 13.7% year-over-year, indicating expansion in its business operations. However, the company is currently unprofitable, with a net margin of -73.2% and a reported net loss in its latest annual statement, reflecting typical early-stage biotech spending patterns on research and development. The company does not pay a dividend, which is common for loss-making firms reinvesting capital into product development and clinical trials.